166 completed. 166 Phase 2, 23 Phase 1, 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 166 | Completed 166 |
| Phase 1 | 23 | Completed 23 |
| Phase 3 | 16 | Completed 16 |
Follow Child Development Disorders, Pervasive: new trials by email Literature Review of Child Development Disorders, Pervasive trials Research Report on Child Development Disorders, Pervasive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models Bumetanide, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 66 | 2025-06-04 | 2026-04-29 |
| Efficacy of Nutritional Supplements on Children With Autism Spectrum Disorder Nutritional supplements, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 88 | 2025-04-01 | 2026-04-23 |
| A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder Low Dose ARD-501, High Dose ARD-501, Placebo - Autism Spectrum Disorder | Phase 2 | Completed | Aardvark Therapeutics, Inc. | 5 | 2024-08-01 | 2025-05-09 |
| Safety and Efficacy of tPBM for Epileptiform Activity in Autism noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - Autism Spectrum Disorder, EEG With Periodic Abnormalities | Phase 2 | Completed | Richard Frye | 6 | 2024-07-01 | 2026-09-22 |
| Effect of Omega-3 Fatty Acid on Neurobehavioral Status of Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo Controlled Trial Omega 3 fatty acid, Placebo of Omega-3 fatty acid softgel capsule - Autism Spectrum Disorder | Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 64 | 2023-09-19 | 2025-07-09 |
| Efficacy and Mechanism of Repetitive Transcranial Magnetic Stimulation in Children With Autism Spectrum Disorders repeated transcranial magnetic stimulation (continuous theta-burst stimulation), sham repeated transcranial magnetic stimulation - Autism Spectrum Disorder | Phase 2 / Phase 3 | Completed | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 200 | 2023-07-04 | 2026-05-19 |
| Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD) Floreo VR Building Social Connections, Sham - Autism Spectrum Disorder | Phase 2 | Completed | Floreo, Inc. | 30 | 2023-02-15 | 2025-02-26 |
| Esketamine Combined With Dexmedetomidine Sedation in Head MRI Examination of Children With Autism Spectrum Disorder low dos dexmedetomidine, high dos dexmedetomidine, dexmedetomidine and esketamine - Autism Spectrum Disorder, Dexmedetomidine | Phase 2 | Completed | Maternal and Child Health Hospital of Hubei Province | 300 | 2022-12-01 | 2024-10-09 |
| Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder NTI164 - Autism Spectrum Disorder | Phase 2 / Phase 3 | Completed | Fenix Innovation Group | 54 | 2022-11-30 | 2026-09-10 |
| Micronutrient Supplementation in Children With ASD Micronutrient - Autism Spectrum Disorder | Phase 2 | Completed | University of California, San Francisco | 16 | 2022-11-14 | 2024-02-29 |
| ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) ML-004 (IR)/(ER) tablet, ML-004 Placebo - Autism Spectrum Disorder | Phase 2 | Completed | MapLight Therapeutics | 168 | 2022-09-13 | 2026-05-19 |
| Autism Spectrum Disorders: Double Blind Randomized Placebo-control Active Pilot Study of Transcranial Magnetic Stimulation Applied to the Superior Temporal Sulcus Transcranial magnetic stimulation, MRI, Neuronavigation - Autism Spectrum Disorders | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 20 | 2022-02-02 | 2026-05-01 |
| A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder L1-79 - Autism Spectrum Disorder, Autism | Phase 2 | Completed | Yamo Pharmaceuticals LLC | 58 | 2022-01-25 | 2024-07-31 |
| A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism Growth Hormone, Saline - Phelan-McDermid Syndrome, Autism Spectrum Disorder (ASD) | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 32 | 2022-01-19 | 2025-04-20 |
| Autologous BMMNCs Combined With Educational Intervention for ASD Autologous BMMNCs transplantation and educational intervention, Educational intervention - Autism Spectrum Disorder | Phase 2 | Completed | Vinmec Research Institute of Stem Cell and Gene Technology | 54 | 2021-12-26 | 2026-01-22 |
| Fatty Acid Supplementation in Children With ASD (Study 2) LCPUFA Oil Supplement, Canola Oil Placebo - Autism Spectrum Disorder | Phase 2 | Completed | Sarah Keim | 98 | 2021-12-01 | 2025-11-13 |
| AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) AB-2004, Placebo - Autism Spectrum Disorder (ASD) | Phase 2 | Completed | Vertero Therapeutics | 156 | 2021-08-02 | 2025-11-21 |
| Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder GWP42003-P, Placebo - Autism Spectrum Disorder | Phase 2 | Completed | Jazz Pharmaceuticals | 103 | 2021-05-31 | 2025-03-30 |
| Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder. FEN164 - Autism Spectrum Disorder | Phase 1 / Phase 2 | Completed | Fenix Innovation Group | 18 | 2021-04-01 | 2026-09-08 |
| A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) Placebo, RO7017773 - Autism Spectrum Disorder (ASD) | Phase 2 | Completed | Hoffmann-La Roche | 104 | 2021-03-31 | 2025-01-28 |
Showing 20 of 166. Sign in to see all of them.
Autistic Disorder (105) · Autism Spectrum Disorder (94) · Asperger Syndrome (16) · Anxiety Disorders (8) · Fragile X Syndrome (7) · Aggression (4) · Attention Deficit Disorder with Hyperactivity (4) · Developmental Disabilities (4) · Epilepsy (3) · Language (3) · Obsessive-Compulsive Disorder (3) · Rett Syndrome (3) · Telomeric 22q13 Monosomy Syndrome (3) · Ataxia (2)
Mental Disorders (164) · Neurodevelopmental Disorders (164) · Autism Spectrum Disorder (72) · Nervous System Diseases (21) · Neurologic Manifestations (16) · Behavior (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Neurobehavioral Manifestations (14) · Genetic Diseases, Inborn (13) · Heredodegenerative Disorders, Nervous System (12) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Congenital Abnormalities (10) · Genetic Diseases, X-Linked (10)
Oxytocin (10) · Aripiprazole (5) · Acetylcysteine (4) · Cognitive Behavioral Therapy (4) · Fatty Acids, Omega-3 (4) · Memantine (4) · Risperidone (4) · Sodium Chloride (4) · Therapeutics (4) · arbaclofen placarbil (4) · Everolimus (3) · Injections (3) · Sertraline (3) · trofinetide (3) · Bumetanide (2)
Stanford University (7) · University of California, San Francisco (7) · Holland Bloorview Kids Rehabilitation Hospital (6) · University of California, Los Angeles (5) · University of North Carolina, Chapel Hill (5) · Evdokia Anagnostou (4) · Forest Laboratories (4) · Arizona State University (3) · Indiana University (3) · Neuren Pharmaceuticals Limited (3) · Assistance Publique - Hôpitaux de Paris (2) · Boston Children's Hospital (2) · Chugani, Diane C. (2) · Drexel University College of Medicine (2) · Emory University (2)
United States (124) · Canada (14) · Australia (6) · China (6) · France (6) · Spain (6) · Italy (4) · New Zealand (3) · South Africa (3) · Vietnam (3) · Belgium (2) · Colombia (2) · Estonia (2) · Hungary (2) · Iceland (2)
Evdokia Anagnostou, M.D. (8) · Linmarie Sikich, MD (5) · Alexander Kolevzon, MD (4) · James McCracken, MD (4) · Antonio Hardan, MD (3) · James B. Adams, PhD (3) · Mustafa Sahin, MD, PhD (3) · Richard P Malone, MD (3) · Robert L Hendren, DO (3) · Alan Percy, MD (2) · Antonio Y Hardan, MD (2) · Bryan King, MD (2) · Ephraim Katz, PhD (2) · Fei Li, MD, PhD (2)
PMID 37811711, PMID 36006807, PMID 37460385, PMID 38114596, PMID 38363467, PMID 10341379, PMID 11918106, PMID 14733976, PMID 17109795, PMID 17352947, PMID 17520797, PMID 17671050, PMID 18315448, PMID 18555170, PMID 19186083, PMID 19309326, PMID 19398354, PMID 19487623, PMID 19491110, PMID 20145986, PMID 20406576, PMID 20620105, PMID 20683766, PMID 21643649, PMID 21883204, PMID 22151477, PMID 22342106, PMID 23097920, PMID 23106988, PMID 23216716, PMID 23357440, PMID 23688534, PMID 23782126, PMID 23978163, PMID 24061784, PMID 24356715, PMID 24472253, PMID 24839884, PMID 24849255, PMID 25187257, PMID 25313065, PMID 25526831, PMID 25685306, PMID 25798215, PMID 25818246, PMID 25878901, PMID 26746121, PMID 26889605, PMID 28122648, PMID 28374207
2009 (1), 2014 (1), 2017 (1), 2018 (1), 2019 (1), 5KL2TR001109-05 (1), P50HD055784 (1), P50MH100023 (1), R01HD091972 (1), R01HD095158 (1), R01MH072263 (1), R01MH073524 (1), R01NS105845 (1), R21MH064941 (1), R21MH080026 (1)